SANCUSO
Drug
Kyowa Kirin, Inc.
Total Payments
$361,251
Transactions
4,922
Doctors
2,493
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10,759 | 530 | 406 |
| 2023 | $5,432 | 271 | 235 |
| 2022 | $2,796 | 88 | 79 |
| 2021 | $6,079 | 230 | 174 |
| 2020 | $191,150 | 237 | 170 |
| 2019 | $23,700 | 479 | 359 |
| 2018 | $43,695 | 736 | 594 |
| 2017 | $77,640 | 2,351 | 1,296 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $155,970 | 51 | 43.2% |
| Food and Beverage | $79,284 | 4,807 | 21.9% |
| Unspecified | $72,844 | 7 | 20.2% |
| Honoraria | $37,875 | 15 | 10.5% |
| Education | $13,750 | 39 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,528 | 3 | 0.4% |
Payments by Type
General
$288,407
4,915 transactions
Research
$72,844
7 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Oral Ondansetron versus Transdermal Granisetron | Kyowa Kirin, Inc. | $22,626 | 0 |
| Sancuso in patients with nausea andor voting from gastroparesis An open label study. | Kyowa Kirin, Inc. | $21,600 | 0 |
| Single-cell RNA sequencing before and after treatment with Mogamulizumab Pegasys of a patient with Sezary Syndrome | Kyowa Kirin, Inc. | $13,949 | 0 |
| Preoperative use of granisetron transdermal patch for prevention of postoperative nausea and vomiting PONV - open label, prospective, pilot study | Kyowa Kirin, Inc. | $10,579 | 0 |
| A Comparative Effectiveness Study of the Enicacy and Safety or Transdermal Graniselron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoictic Stem Cell Trnnsplantntion | Kyowa Kirin, Inc. | $4,090 | 0 |
Top Doctors Receiving Payments for SANCUSO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $86,510 | 18 |
| , MD, PHD | Dermatopathology | Redwood City, CA | $18,600 | 2 |
| , M.D | Dermatology | Scottsdale, AZ | $9,300 | 2 |
| , M.D | Dermatology | Houston, TX | $8,450 | 3 |
| , MD, PHD | Dermatology | Duarte, CA | $8,000 | 3 |
| , MD | Hematology & Oncology | Duarte, CA | $8,000 | 2 |
| , MD | Internal Medicine | Aurora, CO | $7,860 | 2 |
| , MD | Hematology & Oncology | Waterbury, CT | $7,400 | 2 |
| , M.D | Dermatology | Portland, OR | $6,200 | 2 |
| , M.D., PH.D | Dermatology | Pittsburgh, PA | $6,200 | 2 |
| , MD | Dermatology | Duarte, CA | $6,200 | 2 |
| , MD | Medical Oncology | Saint Louis, MO | $5,690 | 3 |
| , M.D | Hematology & Oncology | New York, NY | $5,333 | 7 |
| , M.D | Internal Medicine | Ann Arbor, MI | $5,250 | 2 |
| , MD | Hematology & Oncology | Minneapolis, MN | $5,240 | 2 |
| , M.D., PH.D | Medical Oncology | New York, NY | $5,240 | 2 |
| , M.D | Internal Medicine | Parkersburg, WV | $5,240 | 2 |
| , MD | Internal Medicine | Philadelphia, PA | $5,240 | 2 |
| , M.D, PH. D | Medical Oncology | Charlottesville, VA | $5,240 | 2 |
| , D.O | Internal Medicine | Omaha, NE | $5,240 | 2 |
| , MD | Dermatology | New York, NY | $4,440 | 2 |
| Amitkumar Mehta | Hematology & Oncology | Birmingham, AL | $3,600 | 1 |
| , MD | Medical Oncology | New Haven, CT | $3,108 | 2 |
| , MD | Internal Medicine | Baltimore, MD | $3,100 | 1 |
| Alison Moskowitz | Hematology & Oncology | New York, NY | $3,000 | 1 |
Ad
Manufacturing Companies
- Kyowa Kirin, Inc. $335,764
- Cumberland Pharmaceuticals, Inc. $18,504
- Kyowa Kirin Services Ltd $6,500
- Verity Pharmaceuticals Inc. $483.42
Product Information
- Type Drug
- Total Payments $361,251
- Total Doctors 2,493
- Transactions 4,922
About SANCUSO
SANCUSO is a drug associated with $361,251 in payments to 2,493 healthcare providers, recorded across 4,922 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin, Inc..
Payment data is available from 2017 to 2024. In 2024, $10,759 was paid across 530 transactions to 406 doctors.
The most common payment nature for SANCUSO is "Consulting Fee" ($155,970, 43.2% of total).
SANCUSO is associated with 5 research studies, including "Oral Ondansetron versus Transdermal Granisetron" ($22,626).